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Abstract a-Synuclein is a central component of the patho-
genesis of Parkinson’s disease (PD). Phosphorylation at
serine-129 represents an important post-translational modi-
fication and constitutes the major form of the protein in
Lewy bodies. Several kinases have been implicated in the
phosphorylation of a-synuclein. The targeting of kinase
pathways as a potential to influence the pathogenesis of
PD is an important focus of attention, given that mutations
of specific kinases (LRRK2 and PINK1) are causes of
familial PD. Pramipexole (PPX) is a dopamine agonist
developed for the symptomatic relief of PD. Several in vitro
and in vivo laboratory studies have demonstrated that PPX
exerts neuroprotective properties in model systems of rele-
vance to PD. The present study demonstrates that PPX inhibits
the phosphorylation of a-synuclein and that this is indepen-
dent of dopamine receptor activation. PPX blocks the increase
in phosphorylated a-synuclein induced by inhibition of the
ubiquitin proteasomal system. The phosphorylation of
a-synuclein occurs in part at least through casein kinase
2, and PPX in turn reduces the phosphorylation of this
enzyme, thereby inhibiting its activity. Thus, PPX decreases
the phosphorylation of a-synuclein, and this mechanism may
contribute to its protective properties in PD models.
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Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder characterised in its early stages by the motor features
of bradykinesia, rigidity and tremor, which in turn are related
predominantly to dopamine cell loss in the substantia nigra pars
compacta. This pathology, together with degeneration of other
neurotransmitter systems, is also associated with non-motor
symptoms that evolve with disease progression (Chaudhuri et
al. 2006; Fox et al. 2008; Chaudhuri and Schapira 2009).
Although dopamine replacement therapy can improve quality
of life and life expectancy, a major unmet need in PD is the
ability to slow or stop the progression of neurodegeneration
(Olanow et al. 2008; Schapira et al. 2009).
The pathogenesis of PD is thought to involve a number of
intersecting pathways that include mitochondrial dysfunction,
oxidative stress, lysosomal abnormalities and protein aggre-
gation (Schapira 2006). A substantial number of compounds
have been proposed to have an effect of slowing PD degener-
ation by interfering with these pathways, based mainly on the
results of laboratory studies (Schapira 2009a, b). Dopamine
agonists and monoamine oxidase B inhibitors have demon-
strated neuroprotective properties in a variety of in vitro and in
vivo models of PD and are thought to exhibit antioxidant and
anti-apoptotic properties (for reviews, see Schapira et al. 2009;
Schapira 2009a).
The deposition of a-synuclein as the major constituent of
Lewy bodies and the discovery that mutations and multipli-
cations of the a-synuclein gene are causes of familial PD have
focussed attention on this protein in the pathogenesis of PD
(Fuchs et al. 2008; Ross et al. 2008). It is notable that the
predominant form of a-synuclein in Lewy bodies is phosphor-
ylated at its serine-129 residue (Fujiwara et al. 2002;
Anderson et al. 2006), and this phosphorylation is increased
in A53T a-synuclein expression (Wakamatsu et al. 2007). The
kinase pathways that perform this phosphorylation have not
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yet been fully identified and may involve multiple sequential
stages. The phosphorylated form of a-synuclein can be toxic
to dopaminergic cells and this is increased by oxidative
stress and proteasomal inhibition (Chau et al. 2009). Post-
translational modification in the form of phosphorylation
appears to be of significance to a number of pathways
involved in dopaminergic cell death (Dagda et al. 2009; Obeso
et al. 2010; Schapira and Tolosa 2010; Sha et al. 2010).
Several studies have demonstrated that mitochondrial func-
tion may be influenced by a-synuclein (Devi et al. 2010;
Nakamura et al. 2011), although the role that serine-129 phos-
phorylation may play in this has not been elucidated. The
D2/D3 dopamine agonist pramipexole (PPX) has demonstrat-
ed that it is capable of reducing cell death in toxin models of
dopamine loss in vitro and in vivo and that this may in part be
through an action on mitochondria possibly at the level of the
permeability transition pore (Schapira 2008). Our studies on
PPX and its potential for neuroprotection led us to investigate
the relationship between this compound and a-synuclein phos-
phorylation. We hypothesised that PPXmay reduce phosphor-
ylation at the serine-129 residue site of a-synuclein and that
this contributes to the drug’s protective role in PD models.
Materials and Methods
Cell Culture
A human dopaminergic cell line SH-SY5Y, stably
overexpressing human wild-type a-synuclein tagged with
haemagglutinin (HA) at its C terminus was cultured as
previously described (Chau et al. 2009). Cell culture reagents
were supplied by Life Technologies (Paisley, UK).
Treatments and Samples Collection
Cells were plated at subconfluent density, to which PPX and
its enantiomer SND919CL2x (SND) (Boehringer Ingelheim
GmbH, Ingelheim, Germany), dopamine receptors antagonist
clozapine (Tocris, R&D Systems, Abingdon, UK) and
epoxomicin (Calbiochem, San Diego CA, USA) were added.
5,6-Dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) was
obtained from Enzo Life Sciences (Exeter, UK), whereas
4,5,6,7-tetrabromo-2-azabenzimidazole (TBB) was obtained
from Sigma-Aldrich (Dorset, UK). Where kinase activities
were measured, okadaic acid (OKA; Calbiochem, San Diego
CA, USA) was added to 1 μg/μl 30 min before cells were
harvested. Upon collecting the samples, cells were washed
with phosphate-buffered saline (PBS) twice and lysed in situ
in a buffer containing 1 % Triton X-100, 20 mM Tris–HCl
pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM
Na3VO4 and 50μMNaF. Cell lysates were collected and spun
at 21,000×g at 4 °C for 10 min, and soluble materials were
retained for Western blot analysis. Bafilomycin A1 was
obtained from Sigma-Aldrich (Dorset, UK).
Western Blot Analysis and Densitometry
Equal amounts of protein (as determined by bicinchoninic acid
[BCA] assays; Pierce, Rockford, IL, USA) from the soluble
materials were resolved under reducing conditions in NuPAGE
4–12% polyacrylamide gels (Invitrogen, Carlsbad, CA, USA),
using the MES buffer, and transferred onto Immobilon PVDF
membrane (Millipore, Billerica, MA, USA). Antibodies
detecting HA epitope (Covance, Princeton, NJ, USA),
phospho-serine-129 (P-S129) of a-synuclein (Wako, Neuss,
Germany), a-synuclein (clone LB509; Invitrogen, Carlsbad,
CA, USA), β-actin (Abcam, Cambridge, UK), phospho-
serine-209 (P-S209), pan-casein kinase 2-β (Abcam,
Cambridge, UK) and ubiquitin (Abcam, Cambridge, UK)
were used, and the secondary antibodies detecting mouse
and rabbit IgG were supplied by Dako (Glostrup, Denmark).
ECL reagent (GEHealthcare, Bucks, UK)was used to develop
the immunostained blots, and signals were detected by ECL
films (GE Healthcare, Bucks, UK). Images on X-ray films
were scanned with a trans-illuminating light source and
densities measured using the DigiDoc gel analysis software
(Alpha Innotech, East Sussex, UK).
Measurements on Lactate Dehydrogenase Release
Cell death was quantified by lactate dehydrogenase (LDH)
release as described in Chau et al. (2009) using the kit
manufactured by Promega (Southampton, UK),
Quantification of a-Synuclein Oligomerisation
Total level of a-synuclein was measured using the enzyme-
linked immunosorbent assay (ELISA) kit supplied by Life
Technologies (Paisley, UK). a-Synuclein oligomers was
quantified using the same ELISA kit, with the detection
antibody replaced with the oligomer antibody clone A11
(Life Technologies, Paisley, UK). Data were expressed as
immunoactivity of A11 relative to the antibody detecting the
total level of a-synuclein.
Biochemical Kinase Profiling
In vitro inhibition of a kinase library by 10 μM PPX was
measured commercially by SelectScreen biochemical kinase
profiling (Life Technologies, Paisley, UK).
Proteasomal Activity Measurements
Cells collected, after being washed with PBS twice, were
frozen and thawed three times in 10 mM Tris–HCl pH 7.5.
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Cell lysates were loaded onto a black 96-well plate and mixed
with the respective fluorogenic substrate for PGP, chymotryp-
sin and trypsin-like activities (Calbiochem, San Diego CA,
USA) at 80 μM final concentration. Vmax was measured in a
fluorescent plate reader with the chamber temperature set to
32 °C for 20 min at excitation and emission of 380 and
460 nm, respectively. Vmax was corrected by protein concen-
tration as determined by the BCA assays.
Statistical Analysis
Paired t tests were conducted where two groups were com-
pared, and one-way analysis of variance (ANOVA) followed
byDunnett’s post test was used for multiple comparisons to the
control group. In both cases, p<0.05 was deemed significant.
Results
Pramipexole Decreased the Constitutive Level and Formation
Rate of a-Synuclein Phosphorylation at Serine-129
To establish marker measurements, levels of P-S129 and the
total ectopic level of a-synuclein were measured by Western
blot analysis on 1 % Triton cell lysates, using the antibodies
specifically detecting P-S129 (as demonstrated in Fig. 1 in
Chau et al. 2009 and Fig. S1) and HA, respectively. In our
hands, the endogenous level of a-synuclein in SH-SY5Y
cells is undetectable (Chau et al. 2009 and Fig. S1). We
found no evidence that a-synuclein became Triton-insoluble
under hyper-phosphorylation condition (supported by data
in Fig. 2 in Chau et al. 2009 and Fig. S2), justifying the
examination of only the Triton-soluble cell lysates in our
system.
Figure 1a is a graphical presentation of the data to illus-
trate the time-dependent and dose-dependent relationship of
PPX treatment in decreasing the constitutive P-S129
a-synuclein level. The data have been normalised to the
control (represented as 100 %; mean, 100.5±11.2 %). The
reduction in P-S129 levels became significant at 48 h for 10
or 100 μM PPX and 100 μM for its dopamine receptor
inactive enantiomer SND, with further time-dependent
decreases to 72 h for 100 μM PPX. These data indicate
that the effect on P-S129 is independent of the dopamine
receptors. Further demonstration of PPX acting indepen-
dently of the dopamine receptors came from the use of
the dopamine receptor antagonist clozapine co-incubated
with PPX (Fig. S3). Clozapine had no effect on P-S129
a-synuclein. Figure 1b shows the typical Western blot
images of the cells treated with a range of PPX concen-
trations or its enantiomer SND for a period up to 72 h,
immunostained with the antibody detecting P-S129 and
total levels of a-synuclein and β-actin.
Treatment with the phosphatase inhibitor OKA over
30 min led to an accumulation of P-S129 a-synuclein that
allowed measurement of the rate of P-S129 formation and
the activity of the kinases responsible for phosphorylation
(Chau et al. 2009). Shown in Fig. 1c is a graphical repre-
sentation of Western blot images (normalised to the control
as 100 %; mean, 96.2±5.6 %), and Fig. 1d is a typical image
of the cells treated with 100 μM PPX or SND for a period
up to 72 h, followed by OKA. Our data demonstrate a time-
dependent decrease in the rate of P-S129 a-synuclein for-
mation with PPX or SND treatment, becoming statistically
significant at 72 h. In our system, the kinases contributing to
P-S129 a-synuclein appear to be inhibited by PPX in a
dopamine receptor-independent manner.
Pramipexole Reduced the Proteasome Inhibition-Induced
Level and Formation Rate of a-Synuclein Phosphorylation
at Serine-129
In view of proteasomal inhibition as a model of PD (Imamura
et al. 2008; Li et al. 2010), we studied this effect with
epoxomicin on the levels of P-S129. Epoxomicin (at 14 nM
for 24 h) significantly induced the constitutive level of P-S129
a-synuclein as well as the rate of its phosphorylation
(Fig. 2a–c). Both PPX and its enantiomer SND pre-
incubated for 48 h reduced the rate and levels of P-
S129, increased upon epoxomicin treatment, in a dose-
dependent manner that was significant at 100 μM. These
data suggest that the kinases responsible for P-S129
a-synuclein were upregulated by proteasomal inhibition
and negatively controlled by PPX independently of its
dopamine receptor property.
Influence of PPX on a-Synuclein Phosphorylation
at Serine-129 Induced by Proteasome Inhibition
Does Not Appear to be Related to Cell Viability
and a-Synuclein Oligomerisation
We determined whether PPX prevents cell loss upon
epoxomicin treatment. The 24-h treatment with epoxomicin
at 14 nM caused no noticeable death of SH-SY5Y cells
(data not shown) despite the typical fourfold increase in P-
S129 a-synuclein. Epoxomicin treatment at 14 nM for 72 h
produced a 49±2 % LDH release, but no protection is seen
upon co-incubation with PPX (Fig. S4A) despite the typical
reduction of P-S129 a-synuclein. Similar observations were
made by Imamura et al. (2008) from using another
proteasome inhibitor lactacystin.
We also determined whether increased P-S129 a-synuclein
mediated by proteasome inhibition is associated with
oligomerisation of a-synuclein in vivo. Following treat-
ment with epoxomicin or bafilomycin (known to cause
a-synuclein accumulation and oligomerisation), we
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captured all a-synuclein, followed by detecting either the total
level of a-synuclein or the a-synuclein oligomers by the
A11 antibody using an ELISA approach. Figure S4B
shows that, unlike bafilomycin treatment, epoxomicin
treatment for 24 h produced a small signal of a-
synuclein oligomerisation, and it did not seem to be
influenced by PPX co-incubation. Our observation is
in contrast to that seen in vitro by Kakimura et al. (2001),
in which PPX produced an inhibitory effect on a-synuclein
aggregation induced by H2O2.
a-Synuclein Phosphorylation at Serine-129 was Dependent
on Casein Kinase 2
A number of kinases have been identified to contribute to the
formation of P-S129 a-synuclein (Waxman and Giasson 2008;
Mbefo et al. 2010; Braithwaite et al. 2012). Previously, we
demonstrated that casein kinase 2 (CK2) was responsible
for half of the kinase activity phosphorylating a-synuclein
at serine-129 in our model (Chau et al. 2009). In this
study, a more specific CK2 inhibitor, TBB (used at
10 μM for 30 min), was found to significantly reduce
the constitutive and epoxomicin-induced levels and rates
of generation of P-S129 a-synuclein (Fig. 3a–c). These
data provide additional support for the predominant posi-
tion of CK2 as the kinase in both cases of the constitutive
and induced P-S129 a-synuclein.
Pramipexole Decreases the Abundance of P-S209 of Casein
Kinase 2-β
As the first step to delineate how PPX controls the kinase
responsible for P-S129 a-synuclein, we found that both PPX
and the enantiomer (at 100 μM after 48 h) significantly
reduced the phosphorylation of the β-subunits of CK2 at
serine-209 (Fig. 4a, b), whereas the endogenous expression
of CK2 was unaffected. These data have shed light to the
potential influence of PPX to an upstream signal transduc-
tion pathway of CK2 in phosphorylating a-synuclein at
serine-129.
Pramipexole Does Not Function as an Inhibitor to CK2
In Vitro
Next, we asked the question whether PPX (at 10 μM) func-
tions as a kinase inhibitor in vitro. On a panel of 27 candidate
Fig. 2 PPX-induced D2/D3-independent reduction of the level and rate
of α-synuclein phosphorylation at serine-129 (P-S129) by proteasome
inhibition in SH-SY5Y cells. Epoxomicin (14 nM for 24 h) significantly
(by t test) induced the constitutive level (a) and rate (b) of P-S129,
whereas PPX or SND (when pre-incubated for 48 h and co-incubated
with Epox) decreased the induced level and rate of P-S129, in a dose-
dependent manner, reaching significance (by ANOVA followed by
Dunnett and by t test) at 100 μM. Shown are the mean±SEM signals of
P-S129 corrected by HA of six experiments. c A typical Western blot
image reflecting data shown in a and b
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Fig. 1 PPX, in a D2/D3-independent manner, decreased the constitutive
level and rate ofα-synuclein phosphorylation at serine-129 (P-S129) in SH-
SY5Y cells. PPX, and its enantiomer SND, decreased the constitutive level
of P-S129 (against the total level of α-synuclein–HA), in a time-dependent
and dose-dependent manner (a). Such decrease became significant
(*p<0.05, **p<0.01; by ANOVA followed by Dunnett) upon 100 μM
PPX/SND incubation for 48 h or longer. Shown are themean±SEM signals
of P-S129 corrected by HA of seven experiments. Typical Western blot
results are shown in b. PPX at 100μM(c) decreased the rate of P-S129, in a
time-dependent manner, which reached significance (by ANOVA) by 72 h
incubation. Enantiomer SND at 100 μM caused a statistically significant
reduction after evaluation by t test. Shown are the mean±SEM signals
of P-S129 corrected by HA over a period of 30 min in the presence
of 1 μM OKA of 11 experiments. d A typical Western blot image
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kinases examined, from the standard SelectScreen biochemical
kinase profiling service (Life Technologies, Paisley, UK),
inhibition was ≤10 %, including CK2, glycogen synthase
kinase 3β, Akt that is downstream of phosphatidylinositol
3′-kinase and leucine-rich repeat kinase 2 (Suppl. Table).
These data suggest that PPX does not inhibit the activity of
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Fig. 3 Inhibition of CK2 decreased the level and rate of α-synuclein
phosphorylation at serine-129 (P-S129) in SH-SY5Y cells. Specific CK2
inhibitors DRB and TBB significantly decreased the constitutive level (a)
of P-S129 (against the total level of α-synuclein-HA), as well as the rate
(b) (by t test). Shown are the mean±SEM signals of P-S129 corrected by
HA of three experiments. c Typical Western blot images
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CK2 and/or the kinases responsible for P-S129 a-synuclein
by direct interaction.
Proteasomal Activities Stimulated by Pramipexole
There are some lines of evidence that PPX affects proteasomal
activities (Imamura et al. 2008; Li et al. 2010). Measurements
using fluorogenic substrates on SH-SY5Y lysates enabled us
to estimate proteasomal activities. Although measurements
from three different substrates all produced significant reduc-
tion in activities upon epoxomicin treatment, the ability to
restore the loss of proteasomal activities and to stimulate
proteasomal activities by PPX or SND alone are moderate
(Fig. S5A–C). We also measured the steady-state level of
ubiquitination in our model, which showed a significant
increase in the level of ubiquitinated protein upon epoxomicin
treatment. Although not significant, PPX treatment reduced the
constitutive and epoxomicin-induced level of ubiquitinated
protein (Fig. S5D).
Discussion
In a human dopaminergic cell-based system with stable
expression of a-synuclein, we have demonstrated that the
dopamine agonist PPX can reduce both the level and rate of
phosphorylation of this protein at serine-129. a-Synuclein
P-S129 is the predominant form of this protein in Lewy
bodies, and this post-translational modification may be
important in mediating toxicity (Chau et al. 2009; Kragh
et al. 2009). Both proteasomal inhibition and increased
free radical generation are considered important in PD
pathogenesis (Schapira 2006) and both result in an
increase in P-S129 a-synuclein (Chau et al. 2009),
although the underlying mechanism is not known. The
dopamine receptor inactive PPX enantiomer SND demon-
strated similar properties, implying that the effects on
a-synuclein phosphorylation are not mediated via dopamine
receptor agonist activity. This reduction in a-synuclein phos-
phorylation was produced through a reduction in the rate of
formation of P-S129 modification, suggesting that these com-
pounds could modulate the kinase activity involved. PPX was
also effective in decreasing P-S129 formation induced by
proteasomal inhibition. As illustrated in Fig. 5, we propose
that PPX (in a dopamine receptor-independent fashion)
stimulates proteasomal activities preventing kinase-mediated
P-S129 formation and promoting turnover of P-S129 (which
was shown processed by proteasome; Chau et al. 2009;
Machiya et al. 2010).
In vitro experimentation has suggested that CK1 and
CK2, G protein-coupled receptor kinase 2 and 5 and polo-
like kinase 2 are all capable of phosphorylating a-synuclein
at serine-129 (reviewed by Waxman and Giasson 2008;
Mbefo et al. 2010; Braithwaite et al. 2012). We confirmed
that CK2 inhibitors substantially reduce the phosphorylation
of a-synuclein at serine-129, which supports that CK2 con-
tributes, to a certain extent, to this process in our system.
Our findings that PPX and its enantiomer in turn influenced
b
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Fig. 4 D2/D3-independent decrease in the level of P-S209 CK2-β by
PPX in SH-SY5Y cells. PPX, and its enantiomer SND, decreased the
level of P-S209 (against the total level of CK2-β), in a time-dependent
and dose-dependent (a) manner, significant (*p<0.05; by ANOVA
followed by Dunnett) upon 100 μM PPX/SND incubation for 48 h.
Shown are the mean±SEM signals of P-S209 corrected by the total
level of CK2-β of four experiments. Typical Western blot results are
shown in b
-syn
P-S129
-syn
+ epoxomycin+ PPX / SND
proteasomal activity
turnover
(Fig.1) (Fig.S3)
(Fig.2) (Chau09)
(Fig.S5)
DRB / TBB-sensitive i.e. CK2-dependent (Fig.3)
proteasomal activity
P-S209 CK2-dependent (Fig.4)
Fig. 5 Schematic diagram outlining the potential influence of PPX for
P-S129 α-synuclein in this study. Items in black are derived from
definite experimental evidence, whereas those in grey are descriptive
578 J Mol Neurosci (2013) 51:573–580
the phosphorylation of the β-subunits of CK2 at serine-209
(Bodenbach et al.1994; Litchfield 2003) provide a possible
mechanism for how these compounds reduce a-synuclein
phosphorylation by modulating the CK2 signalling pathway
and the potential protective effect of PPX. However, our
limited in vitro kinase profiling indicates that PPX did not
inhibit many candidate kinases at 10 μM level.
In the same cell line used in these experiments and at
similar concentrations used here, both PPX and SND have
demonstrated protection against the toxins 1-methyl-4-
phenylpyridinium, rotenone, paraquat, hydrogen peroxide
and lactacystin (Gu et al. 2004; Iravani 2008; Ferrari-
Toninelli et al. 2010). It has been proposed that PPX may
exert its protective effects through several pathways, including
mitochondrial protection, anti-apoptotic, anti-inflammatory
and growth factor-like effects (Gu et al. 2004; Presgraves et
al. 2004; Du et al. 2005; Izumi et al. 2007; Iravani et al. 2008).
A protective effect has also been seen in primates in MPTP
toxicity in vivo (Iravani et al. 2006) and in rodents against
lipopolysaccharide-induced inflammation (Ferrari-Toninelli
et al. 2010) and proteasomal inhibition (Imamura et al.
2008; Li et al. 2010). Our current finding that PPX reduced
a-synuclein phosphorylation may provide a mechanistic
explanation to the proteasome impairment model. It is
worth investigating the neuroprotective effect of PPX in
this model. The decrease in P-S129 induced by PPX
adds an additional candidate pathway for the protective
effects seen.
These results have several interesting implications. A
double-blind randomised delayed start study of PPX in early
PD has just been completed (Schapira et al. 2010). If the
reduction in formation of P-S129 is a significant pathway
contributing to protection, it might be expected to have a slow
cumulative effect, reflecting the gradual but progressive evo-
lution of the disease (Braak et al. 2003). The action on P-S129
does not seem to be dependent upon the activation of the
dopamine receptor and so it is possible that any protection
might be seen in dopaminergic and non-dopaminergic
pathways, i.e. any neuron in which Lewy bodies form.
This is important, as a significant component of PD
morbidity is determined by non-dopaminergic degenera-
tion. Finally, the phosphorylation pathway of a-synuclein
may represent a valid target for drug discovery in PD in
terms of developing additional compounds for investigation
as protective agents.
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